Surrozen is focused on harnessing the regenerative potential of the Wnt signaling pathway to develop innovative therapeutics for various diseases. The company is advancing a pipeline of disease-specific antibodies aimed at treating conditions with significant unmet medical needs, particularly in the areas of severe alcohol-associated hepatitis, retinopathies, and age-related macular degeneration. By identifying disease states that respond to Wnt pathway modulation, Surrozen designs tissue-specific antibodies that can repair damaged tissues, restore organ function, and ultimately improve patients' quality of life.

The company's research emphasizes the role of Wnt signaling in tissue maintenance and regeneration, with a particular focus on its applications in the liver and eye. Surrozen's approach includes the development of selective Wnt mimetics and agonists that activate the Wnt/β-catenin signaling pathway in targeted tissues. This strategy aims to create therapeutics that not only address the symptoms of diseases but also promote healing and regeneration at a cellular level, thereby offering hope for patients suffering from debilitating conditions.

United States

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal

Surrozen

Company Details